Name Ruian ( Ray) Xu (PhD Otago) 许瑞安

Mailing Address:

Professor and Director

Engineering Research Center of Molecular Medicine

Ministry of Education

518/519 Shengjun Building

Huaqiao University Main Campus

Fujian, CHINA 362021

Tel：0086-0592-61612998/0086-59522690952

Fax: 0086-59522690535

Email: ruianxu@hqu.edu.cn

国家教育部分子药物工程研究中心主任、
国际癌细胞与基因疗法学会常务理事、
国际口服基因疗法主要奠基人和发明人之一、
国家科技部科技发展战略专家/国际科技合作管理专家
国家教育部学位中心评审专家
福建省生物医药工程研究生培养基地负责人
华侨大学分子药物所所长
厦门海洋与基因工程重点实验室主任
厦门市国际科技合作分子药物基地负责人、教授、博士生导师
瑞典卡罗琳医学院国际学术刊物Islet编委
美国International Panel of Medical Science Monitor
我国World Journal of Gastroenterology Pharmacology and Treatment 编委
美、英、德、日、瑞典等国际18家Hepatology，Gene Therapy等SCI 学术刊物审稿人
“行政院”台北荣民总院荣誉教授
爱尔兰国家自然基金评审专家
新西兰食品科学技术研究院专业委员
北京协和医学院荣誉教授
《中国临床药理学和治疗学》编委、顾问，
《中国海洋资源》特邀编委、
中国海洋大学海洋药物客座教授，
山东大学兼职教授
国家863“十五”肺癌基因疗法课题组组长、首席科学家
肝癌基因疗法课题组副组长、
国家863“十一五”肺癌基因疗法课题组首席科学家

1983 年录取教育部出国公派留学，1989年获得Otago 大学博士学位，在加拿大完成博士后，一直在国外多家著名国际大学、科研机构从事科研教学工作，先后出任过大学载体研究中心、神经载体研究室主任。其分子药学研究工作发表于Nature Medicine[文章发表于1998年第5期封面]、Science、PNAS等国际一流学术刊物。从1983年起至今已发表学术论文100余篇，其中SCI论文70余篇；并申报/获得专利发明16项。2005 年发表在美国的?医学科学检测? 杂志的“Stability of Infectious rAAV vector stock ”一文被联合国科教文机构下属世界卫生组织定为分子疗法临床应用的主要参考文献之一。

合编《Trends in Gene Therapy Research》NOVA Science Publisher, New York, USA(2005)。主编《分子基因药物学》北京大学出版社 & 北京大学医学出版社 110万字（被选为我国2008年最佳科技图书），《细胞工程与分子生物技术》化学工业出版社 70万字，2007 年入选美国Marquis 科学工程版Who is who。 2008年入选美国Marquis 国际版Who is who。2010年 获中国侨界双百奖（创新人才奖）。2010年第二届国际定量药理学与新药评价会议主席。2011年荣获“科学中国人” 年度人物。

部分研究工作发表于Nature Medicine[1998年第5期封面]、Science、PNAS等国际一流学术刊物。“科学中国人” 年度人物 。

研究方向： 分子药物、分子医学、海洋与基因工程药物

Education: PhD, Otago University, NZ （1989-05-06）

PATENT APPLICATIONS:(16)

No.	Name of Inventors	Application Number	Title of Patent
1	RA Xu, X., Ma	200310102910.2	Transducting intestine cells by oral gene delivery
2	RA Xu， Y., Diao，K., Cai	200710133914.5	Vasostatin for inhibiting lung cancer metstasis
3	RA Xu; G.,Wang, Y. Diao	200510094205.1	Production and application of recombinant cytoglobin
4	D Zheng; RA Xu, H Ma, Y Liu, X Kung	03138357.2	A recombinant soluble tumor necrosis factor-related apoptosis-inducing ligand sequence and application
5	RA Xu, X Sun, ST Fang, X Kung, G·Kressen	200480005187.9	Synergizing with angiostatin adeno-associated virus-mediated B7.1 vaccination to eradicate the spread of metastatic tumor
6	RA Xu, X L, P Fung	200480021790.6	A drug for prevention and treatment of liver cirrhosis
7	RA Xu, L Tse, Y Diao	200510134979.2	Two kinds of novel angiogenesis inhibitor drugs and their application to Combat Cancer
8	RA Xu, P Fung, J Zhu	200610097384.9	Methodology and application of A anti-colon cancer gene mediecine
9	Y Diao; RA Xu	200610098354.X	Of an anti-cardiovascular and cerebrovascular diseases, traditional Chinese medicine composition and its preparation method
10	Q Zeng; RA Xu	200710132230.3	A Method for preparation of ethyl cinnamate derivatives
11	RA Xu, W Xiao, H Lu	200910136134. 5	A new type of cell-specific microRNA binding gene sequence containing HAAVmir for gene therapy
12	黄晓平;李招发;刁勇;许瑞安	200910263224.0	一种分泌表达人Kallistatin的重组酵母菌株及生产工艺
13	许瑞安，张亭亭、李招发、刁勇	201010189909.8	重组细胞球蛋白在延缓皮肤衰老中的应用
14	许瑞安，吴龙火	201010142730.9	一种 (±)-Murracarpin的合成方法及其抗炎作用
15	许瑞安，施伟杰	201011113349.0	融合Tat人源细胞球蛋白及其在治疗肝癌中的应用
16	许瑞安、王晓	201010142737.9	鳄鱼鳞的提取及其临床应用

PUBLICATIONS

I. Total Chapters of Books: 15

1. 1 Chapter Xu RA* et al. Oral viral gene delivery （33pages）, In: Trends in Gene Therapy Research （2006） NOVA SCIENCE，Publisher, New York, USA （An invitation to Xu RA from NOVA Science Publisher, New York, USA）

2. 9 Chapters In: Molecular Gene Medicine。Xu RA*, Chen L, Xiao WD

(Es), Peking University Press & Peking University Medical Press, 2008.2

《分子基因药物学》 许瑞安*、陈凌、肖卫东主编 110万字 北京大学出版社 & 北京大学医学出版社联合出版， 2008年， 北京。

① Chapter 3 Molecule drug delivery channels and intestinal absorption of nano-particles RA Xu* pp68-90

② Chapter 4 Aptamer Molecular Pharmacology J Lin、RA Xu pp 91-104

② Chapter 7 Molecular therapy of Parkinson's disease and Prospects Jia L, RA Xu pp 175-205

④ Chapter 8 Molecular therapy of hepatitis B Li H、RA Xu* pp 206-245

⑤ Chapter 10 Molecular treatment of the liver cirrhosis Li,X, Y Lv, RA Xu* pp 272-301

⑥ Chapter 13 Diabetes gene drug R & D Liu Q., Cai S, RA Xu* pp 346-390

⑦ Chapter 14 Cranial mandibular defect repair of modern medicine Diao Y., RA Xu* pp 391-432

⑧ Chapter 15 Molecular pathogenesis and therapy of lung cancer Wang Q, Y Diao, RA Xu* pp 433-525

⑨ Chapter 16 New treatment for liver cancer Sun, X., RA Xu* pp 525-565

⑩ Chapter 17 Molecular therapy of colon cancer Lv Y., Wang Q., RA Xu* pp 566-627

? Chapter 18 Stem cells and cancer stem cells Wang Q, Y Lv, RA Xu* pp 628-678

3. 5 Chapters In: Cell Engineering and Biotechnology Diao Y, Xu RA (Es)

Chemical Industry Press, Peking, 2008

《细胞工程与生物技术实验指南》 刁勇 许瑞安*主编 70万字 化学工业出版社

2008 年， 北京。

① Chapter 1 Infrastructure of Cells and biotechnology X Wang X, W Shi, RA Xu pp 1-9

② Chapter 6 Induction of cell differentiation technology W Tang, RA Xu* pp 167-197

③ Chapter 9 Mammalian cells RNAi Q Wang、RA Xu* pp221-258

③ Chapter 13 Cells and recombinant virus vector technology F. Wang, RA Xu* pp306-337

⑤ Chapter 16 Application of Cellular Biotechnology Liu J, Y Diao, RA Xu* pp379-415

4. 1 chapter In:

Chapter 6 Biologics R & D and pharmacodynamic evaluation of route of administration of drugs--- Gene drug route of administration and efficacy evaluation of Efficacy RA Xu* H Luo

2. Total Peer Review Articles ( > 100 )

List of Recent 12-year Peer Review Articles

1 Zhang G, Wang Q, Xu RA* Therapeutics Based on microRNA: An New Approach for Liver Cancer. Current Genomics, 11(5), 311-325, 2010 PubMed ID (20) DOI: 10.2174/ 138920210791616671

2 Lu H, Qu, G, Ding Q, Wang X, Xu RA, Xiao W A new type of cell-specific microRNA binding gene sequence containing HAAVmir for gene therapy Human Gene Therapy (2011) PubMed ID:(18500941)

3 Lijuan Xie, Jingnan Cui, Xuhong Qian, Yufang Xu, Jianwen Liu, R.A.Xu. 5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior. Bioorganic & Medicinal Chemistry 2011; 19 (2): 961-967.

4 Diao Yong, Zhao Xiaofeng, Lin Junsheng, Wang Qizhao, R.A.Xu*. Protection of the liver against CCl4-induced injury by intramuscular electrotransfer of a kallistatin-encoding plasmid World J Gastroenterol 2011 Jan; 17(1): 111-117.

5 Wu Longhuo, Li Pei, Wang Xiao, Zhuang Zhenjing, Farzaneh Farzin, R.A.Xu*. Evaluation of anti-inflammatory and antinociceptive activities of Murraya exotica. Pharmaceutical biology 2010; 48(12):1344-53. PubMed ID (20738224)

6 William Xu, Qi Zhao Wang, Qi Cui, R.A.Xu**. MicroRNA polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility. Current Pharmacogenomics and Personalized Medicine. 2010 Dec; 8(4): 289-305(17).

7 Tang Mq Tang M, Xu W, Wang Q, Xu RA*. DNMT and its related epigenetic regulation in lung tumorigenesis. Current Genomics, 2009;10(5):336-52 PubMed ID (20119531) SCI

8 Wu L, Wang X, Xu W, Farzaneh F, Xu RA*. The Structure and pharmacoligical functions of coumarin and their deveritives Current Medicinal Chemistry 2009; 16(32): 4236-60. PubMed ID (19754420)

9 Sun X, Jiang H, Jiang X, Tan H, Meng Q, Sun B, Xu RA, Krissansen GW Antisense hypoxia-inducible factor-1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats. Hum Gene Ther. 2009 20(4):314-24. PubMed ID (19327024).

10 Wang Q, Xu W, Habib N, Xu RA*. Potential uses of microRNA in lung cancer diagnosis, prognosis and therapy. Current Cancer Drug Targets, 2009, 9（4）:572-594 PubMed ID (19754420)

11 Jiang X, Li H, Qiao H, Jiang H, Xu R, Sun X Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009;100(11):2226-33. PubMed ID (19709125).

12 Lv Y, Wang Q, Diao Y, Xu RA*. Cytoglobin: Novel Potential Gene Medicine for Fibrosis and Cancer Therapy. Current Gene Therapy, 2008，8，287-294 PubMed ID: (18691024 )

13 Lv Y, Wang Q, Xiao W, Diao Y, Xu RA* Trends in development of self-complementary adeno-associated virus vector Sheng wu gong cheng xue bao = Chinese journal of biotechnology 2009, 25(5):658~66 PubMed ID: (19670632 )

14 Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu R, Sun X Down-regulating hypoxia-inducible factor 1 alpha augments transcatheter arterial embolization to treat hepatocellular carcinomas in rats. Human Gene Therapy (2008) (Epub 22 Dec 2008), PubMed ID:(19102662)

15 Diao Y, Ma J, Li X, Sun X, Xu R. Construction and activity of recombinant adeno-associated virus expressing vasostatin. Sheng wu gong cheng xue bao = Chinese journal of biotechnology 24 (11) , 1949-54 (2008) PubMed ID:(19256344)

16 Wang Q, Lv Y, Xu RA*. The design of vectors for RNAi delivery system. Curr Pharm Design 2008 14（13）：1327-1340. (An invitation from Editor-in-chief to Xu RA) PubMed ID:(18537656)

17 Lu H, Chen L, Wang J, Huack B, Sarkar R, Zhou S, Xu R, Ding Q, Wang X, Wang H, Xiao W. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Human Gene Therapy 19 (6) , 648-54 (2008) PubMed ID:(18500941)

18 Tse LY，Sun X*, Jiang H, Dong X, Fung PWC, Farzaneh F, Xu R*. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular varcinomas. J Gene Med 2008, 10 (5) , 508-17 PubMed ID:(18338836)?

19 Li H, Li XY, Lam, KS, Cheung T, Xu RA* Adeno-associated virus-mediated pancreatic and duodenalmhomeobox gene-1 expression enhanced differentiation of hepatic oval stem cells to insulin-producing cells in diabetic rats. J Med Sci, 2008 15,487-497 PubMed ID:(18253862 )

20 Cai, K, Tam P, Xu RA, Shan MH. Suppression of lung tumor metastasis in mice by recombinant adeno-associated virus-mediated expression of vasostatin Clin Cancer Res 2008, 14 (3) , 939-49 PubMed ID:(18245558 )

21 Rabie AB, Dai J, Xu RA. Recombinant adeno-associated virus mediated vascular endothelial growth factor gene therapy induces mandibular condylar growth. Gene Ther 2007, 14, 972–980 PubMed ID:(17460722 )

22 Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu RA, Sun X. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer 2007, 121(2):416-24 PubMed ID:(17330237)

23 Wang D, Liu W, Han B, Xu R. Biochemical and enzymatic properties of a novel marine fibrinolytic enzyme from Urechis unicinctus. Appl Biochem Biotech 2007 136(3):251-64. PubMed ID:(17625232 )

24 Xu RA, Harrison, PM, Chen, M,Li, XY, Tsui T-Y, Fung PCW, Cheung P-T, Guangji Wang G, Li H, Diao Y, Xu S, Krissansen GW, Farzaneh F. Cytoglobin protects against damage-induced liver fibrosis. Mol Ther 2006, 13(6):1093-100 PubMed ID:(16581302 )

25 Xu RA, Zhao B, Fung P, Li XY. Histology and histopathology 2006，21：587-92 (An invitation from Editor-in-chief, Professor Hernz-calvo to Xu RA) PubMed ID:(16691539 )

26 Bernd H, Xu RA, Xie J, Ding Q, Sipler M, Wang H, Chen, L, Xiao WD. An efficient AAV1/AAV2 hybrid vector for gene therapy of Hemophilia. Human Gene Therapy 2006, 17(1):46-54. PubMed ID:(16409124)

27 Ma H, Liu Y, Liu S, Xu RA*, Zheng D*. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005, 42(6):1355-63. PubMed ID:(15800912 )

28 Shi J, Liu Y, Guo J, Zhang D, Zheng D, Li X, Cheung P-t, Farzaneh F, Xu RA*.　Expression of an anti-DR5 single chain antibody in muscles of nude mice prevents lung cancer growth. Cancer Res 2006, 66(24):11946-53. PubMed ID:(15753363)

29 Lee TK, Man K, Ho JW, Wang HX, Poon RT, Sun KW, Ng KT, Ng IO, Xu RA, Fan ST. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005, 11(23):8458-66. PubMed ID:(16322309)

30 Tsui TY, Lau CK, Wu X, Wang YQ, Siu YT, Xu RA, Schlitt HJ, Fan ST Hemo oxygnase-1 gene therapy attenuates micronodular Liver cirrhosis in rat. Hepatology 2005, 42(2):335-42. PubMed ID:(16025519 )

31 Ma H, Zheng D*, Liu Y, Liu S, Kung HF, Sun X, Xu RA*. AAV-Mediated TRAIL gene therapy suppresses liver metastatic tumors. International Journal of Cancer 2005, 116(2):314-21. PubMed ID:(15800912 )

32 Chen M, Wang GJ, Diao Y, Xie H, Li X, Sun J, Xu RA. AAV-mediated interferon-gamma ameliorates the hepatic fibrosis in vitro and in vivo. World J Gastroenterology 2005, 11(26):4045-51. PubMed ID:(12883531)

33 Wang DL, Hu Q, Xu RA*. The bioreactor: a powerful tool for large-scale preparation for animal cells. Curr Pharm Biotech 2005, 6(5):397-403.

34 Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu RA*. Over-expression of soluble tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005, 65:1687-92. PubMed ID:(15753363)

35 Sun X, Qiao H, Jiang H, Zhi X, Liu F, Wang J, Liu M, Dong D, Kanwar JR, Xu RA, Krissansen GW. Intramuscular delivery of anti-angiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Ther 2005, 12 (1) 35-45. PubMed ID:(16211089)

36 Xu RA*, Ma H, Fung PCW, Chang Q, Xu S, During MJ Stability of infectious recombinant AAV vector. Medical Science Monitor 2005, 11(9) BR305-308 PubMed ID:(16127351)

37 Dai J, Rabie AB, Hagg, EUO, Xu RA*. A novel strategy for repair of craniofacial bone defects. Curr Gene Ther 2004, 4(4):469-85; PubMed ID:(15578995)

38 Lee TK, Man K, Ho JW, Wang HX, Poon RT, Sun KW, Ng KT, Ng IO, Xu RA, Fan ST. The significance of RAC-signaling pathway in HCC cell motility: Implication for a new therapeutic target. Carcinogenesis 2005,26(3):681-7PubMed ID:(15604094)

39 Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu RA, Fan ST. FTY 720 induce apoptosis of human hepatoma cell lines through PI3-K mediated Akt dephosphorylation. Carcinogenesis 2004, 25 (12) 2397-405. PubMed ID:(15297371 )

40 Ma H, Liu YX, Liu SL, Xu RA, Zheng DX. Expression of TRAIL (114-281) mediated by adeno-associated virus and its tumoricidal activity. Zhonghua Yi Xue Za Zhi 2004, 84 (19):1635-41. PubMed ID:(15569460)

41 Tu SP, Cui JT, Liston P, Jiang XH, Xu RA, Lin MCM, Zhu YB, Zou B, Samuel SM Ng, Xia HX, Wong WM, Chan OO, Yuen MF, Lam SK, Kung HF, Wong BCY. Gene therapy for colon cancer by adeno-associated virus-mediated transfer of surviving Cys84Ala mutant. Gastroenterology 2005, 128 (2): 361-75. PubMed ID:(15685548 )

42 Sun X, Krissansen GW, Fung PWC, Xu S, Shi J, Man K, Fan ST, Xu RA*. Anti-angiogenic therapy subsequent to adno-associated virus mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int J Cancer 2005, 113 (4) 670-7. PubMed ID:(15472906)

43 Tsui TY, Lau CK, Ma J, Wu X, Wang YQ, Farkas S, Xu R, Schlitt HJ, Fan ST. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: A new approach to attenuate liver fibrosis in rats. Hepatology 2005: 335-42 PubMed ID:(16025519 )

44 Sun X, Qiao H, Jiang H, Zhi X, Liu F, Wang J, Liu M, Dong D, Kanwar JR, Xu R, Krissansen GW. Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors. ancer Gene Ther. 2005 Jan;12(1):35-45. PubMed ID:(15486558)

45 Xu RA*, Sun X, Tse LY, Li H, Chan PC, Xu S, Xiao W, Kung HF, Krissansen GW, Fan ST. Long-term expression of angiostatin and suppression of liver metastatic cancer. Hepatology 2003, 37:1451-61. PubMed ID:(12774025)

46 Li XY, Xu RA, Wang GJ, Xie HT, Zhao XC, Chen M. Effects of rAAV/rSTAP on mRNA Lever of interstitial collagenase in rat stellate cell. Chin J Clin Pharmacol Ther 2004, 9 (11):1236-8.

47 Cai KX, Sham MH, Zheng DX, Xu RA*. Anti-HBV medicine and treatment. Chinese Journal of Internal Medicine 2003, 50:744-6.

48 Chen Y, Luk KDK, Cheung KMC, Xu RA*, Lin M, Lu WW, Leong JCY, Kung HF. Gene therapy for new bone formation using an adeno-associated viral bone morphogentic protein-2. Gene Therapy 2003, 10:1345-53. PubMed ID:(12883531)

49 Xu RA*, Cai KX, Zheng D, Ma H, Xu S, Fan ST. Molecular therapeutics of HBV. Curr Gene Ther 2003, 3(4): 341-55. PubMed ID:(12871021 )

50 Shi J, Zheng DX, Man K, Fan ST, XU RA*. TRAIL: A potential agent for cancer therapy. Curr Mol Med 2003, 3: 727-736. PubMed ID:(14682494 )

51 Ma H, Xu RA, Cheng H, Kuo HS, During MJ, Fang RH. Gene transfer into human keloid tissue with adeno-associated virus vector. J Trauma 2003, 54 (3): 569-573. PubMed ID:(12634540)

52 Cai, KX, Sham MH, Tam P, Lam WK, Xu RA*. Lung cancer gene therapy. Gene Ther Mol Biol 2003, 7:255-72.

53 Xu RA*, Li H, Tse L, Kung HF, Lu H, Lam KSL. Diabetes gene therapy: potential and challenges. Curr Gene Ther 2003, 3(1):65-83. PubMed ID:(12553537 )

54 Diao Y, Xu RA, Wang GJ, Zhao XC. Adeno-associated virus mediated expression of human erythropoietin in vitro. Acta Pharmacol Sin 2002, 23 (1): 55-58. PubMed ID:(1186073 )

55 Jung SC, Han IP, Limaye A, Xu RA, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P. Adeno-associated viral vector-mediated gene transfer results in log-term enzymatic and functional correction in multiple organs of fabric mice. Proc Natl Acad Sci USA 2001, 98: 2676-81. PubMed ID:(11226298 ) (IF 10.5)

56 Mastakov M, Baer C, Xu RA, Fitzsimons H, During MJ. Combined injection of AAV with manitol into rat brain. Mol Ther 2001, 3: 225- 32. PubMed ID:(11237679)

57 Xu RA, Janson CG, Mastakov M, Lawlor P, Young D, Mouravlev A, Fitzsimons J, Choi KL, Ma H, Dragunow M, Leone P, Chen Q, Dicker B and During MJ. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther 2001, 8:1323-32. PubMed ID:(11571569)

58 During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons H, Poulsen D, Leone P, Xu RA, et al An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000, 287: 1453-60. PubMed ID:(10688787) (IF 29.6)

59 Dragunow M, Xu R, Walton M, Woodgate A, Lawlor P, MacGibbon GA, Young D, Gibbons H, Lipski J, Muravlev A, Pearson A, During M. c-Jun promotes neurite outgrowth and survival in PC12 cells. Mol Brain Res 2000, 83(1-2): 20-33. PubMed ID:(11072092)

60 Walton M, Woodgate A, Muravlev A, Xu R, During M, Dragunow M. CREB phosphorylation promotes nerve cell survival. Journal of neurochemistry 73 (5) , 1836-42 (1999) PubMed ID:(10537041 )

61 During MJ, Xu RA, Young D, Kaplitt M, Sherwin R, Leone P Peroral gene therapy of lactose in tolerance using an adeno-associated virus vector. Nat Med 1998, 4: 1131-6. PubMed ID:(9771745)

62 Wang Q，Lv Y, Xu RA*. Dose-response and control of adeno-associated viral vectors based preclinical and clinical gene therapy. Chinese Journal of Clinical Pharmacology and Therapeutics. 2008, 1:1182-1194.

63 Lv Y, Q, Wang, Y Diao, RA Xu* Optimization of the Transfection Efficiency of Human Hepatic Stellate Cell and Hepatocyte Using Liposome. Journal of HuaqiaoUniversity (Natural Science). 2010, 31(1): 49-52.

64 Wang Q, Lv Y, Xiao W, Diao Y, Xu R*. The clinical researches of recombinant adeno-associated vectorr. China biotechnology, 2010, 31(1):73-79

65 Wang Q, Diao Y, Lv Y, Li Z, Xu R. Mutant K-ras-specific siRNA inhibits proliferation, migration and induces apoptosis of lung cancer A549 cells. Chin J Cancer Biotherapy, 2009, 16(6):564-9.

66 Diao Y, Wang Q, Lv Y, Xu R. Hurdles and solutions to noninvasive pulmonary delivery gene medicine. Chinese Journal of New Drugs and Clinical Remedies, 2009, 08: 571-575

67 Huang X, Wang X, Dong H, Zhao X, Li Z, Wang Q, Xu R, Diao Y. High level expression of recombinant human kallistatin in Pichia pastoris and its bioactivity. Chin J Biotech, 2010,26(2):249~255

68 XU RA* Exploring oral delivery of medical nanoparticle and gene medicine Chinese Journal of Clinical Pharmacology and Therapeutics 2007,12: 1092-1097.54.

69 Wang F, Diao Y, Xu RA* Large scale production of adeno-associated viral vectors for clinical trials China biotechnology 2010

70 Diao Y, Xu R Oral devivery of adeno-associated viral vectors Yao Xue Xue Bao. 2009 Jul;44(7):703-9. PubMed ID:(19806906 )

71 吴龙火, 许瑞安*. 九里香中香豆素Paniculal的化学合成途径. 海峡药学, 2010, 22 (1):168-169.

72 王启钊, 吕颖慧，李招发，刁勇，许瑞安*. 腺相关病毒的衣壳装配和DNA衣壳化机制 生物工程学报 in press.

73 王启钊，李招发，江楠，刁勇，许瑞安*. 铁过载氧化应激模型的构建、检测与分析. 中国临床药理学与治疗学. In press.

74 龚玉华, 王启钊, 许瑞安*. 非组蛋白HMGA2: 抗肿瘤药物的新靶标．中国药物杂志. 2010 Nov; 45(2):1694-1700.

75 王启钊, 吕颖慧, 肖卫东, 刁　勇, 许瑞安*. 重组腺相关病毒载体临床实验研究. 中国生物工程杂志, 2010, 30 (1): 73-79.

76 卢　超, 王启钊, 许瑞安*. 重组腺相关病毒载体的整合性研究进展 生命科学, 2010, 22(5): 459-465.

77 卢超, 万江波, 唐明清, 肖卫东, 许瑞安*. 重组腺相关病毒载体的免疫性研究及其解决策略. 中国临床药理学与治疗学, 2010 May; 15 (5): 577-583.

78 刁　勇*，许瑞安. 重组腺相关病毒基因药物的细胞免疫毒性及对策. 药学学报. 2010, 45 (9): 1071?1077.

79 黄晓平, 王　晓, 董　浩, 赵小峰, 李招发, 王启钊, 许瑞安, 刁　勇*. 重组人可溶性TRAIL 在毕赤酵母中表达与纯化及其抗肿瘤细胞活性. 中国生化药物杂志. 2010, 31(2):73-77.

80 黄晓平，王晓，董浩，赵小峰，李招发，王启钊，许瑞安，刁勇*. 重组人kallistatin 蛋白在毕赤酵母中的高效表达及生物活性分析. 生物工程学报. 2010 Feb; 26(2): 249 - 255.

81 吕颖慧，王启钊，刁勇，许瑞安*. 脂质体转染人肝星状细胞和肝细胞条件优化. 华侨大学学报(自然科学版), 2010, Jan; 31(1): 49-52.

82 梁丽英，张国海，许瑞安*. 脂肪酸合成酶抑制剂研究热点及其开发.中国现代应用药学. 2010 April; 27(4): 300-303.

83 熊亚楠, 李招发, 许瑞安*. 纤溶酶系统与阿尔茨海默症. 生命的化学. 2010; 30(1):76-80.

84 王启钊, 吕颖慧, 江　楠, 刁　勇, 许瑞安*. 干细胞不均匀分裂与肿瘤发生. 癌症. 2010; 29(3): 265-271.

85 刘建福, 范燕萍, 许瑞安*. 福建泉州地区珍稀野生药用植物资源与保护. 热带作物学报. 2010 Feb; 31 (2): 284-291.

86 ZHAO Yong-Gang, LI Hua, XU William2, LUO Jia, XU Rui-An*. An Overview of the Fibrinolytic Enzyme from Earth-worm. 中国天然药物. 2010 Jul; 8(4): 301-308.

87 施伟杰, 毕丽伟, 许瑞安*. 联合细胞穿膜肽的肿瘤靶向载体. 中国肿瘤生物治疗杂志. 2010 Feb; 17(1): 104-114.

88 李　培, 邱　飞, 吴龙火, 许瑞安. 多功能信封式纳米载体研究进展. 中国生物工程杂志. 2010; 30(6): 139-143.

89 吴龙火, 许瑞安*. 简单香豆素药理作用与构效关系研究进展. 医药导报. 2010 Apr; 29(14): 498-501.

90 毕丽伟, 施伟杰, 许瑞安*. 细胞衰老与慢性肝病及对肝纤维化的调节作用. 江苏预防医学. 2010 Mar; 21(12):67-69.

91 唐明青, 王启钊, 许瑞安*. 癌基因成瘾-肿瘤分子靶向药物研发的一种新思路. 中国肿瘤生物治疗杂志. 2010 Apr; 17(2): 213-220.

92 曾庆友, 许瑞安. 阿魏酸乙酯的一锅法合成. 中国医药工业杂志. 2010; 41(4): 255-256.

93 张国海, 梁丽英, 许瑞安*. RNA干扰抗丙型肝炎病毒的研究进展. 重庆医学, 2010 Jul; 39(14): 1914-1917.

94 张国海, 王启钊, 张景红, 许瑞安*. microRNA调控的靶向性病毒载体在基因治疗中的应用. 生物工程学报. 2010 Jun; 26(6): 707-714.

95 王启钊, 刁勇, 吕颖慧, 李招发, 许瑞安*. 突变型K-ras siRNA对肺癌细胞的影响. 中国肿瘤生物治疗杂志. 2009, Accepted.

96 王峰、刁勇、许瑞安* 重组腺相关病毒规模化生物包装技术. 生物工程学报2009, November 25; 25(11): 1608-1613

97 王启钊, 吕颖慧, 许瑞安* 肿瘤基因治疗的一点思路. 中国肿瘤临床, 2009, Accepted.

98 罗海涛 许瑞安 肿瘤干细胞研发热点 生命科学， 中国上海 2009 Accepted.

99 张亭亭，李招发，许瑞安* 重组可溶性细胞球蛋白的制备、纯化与抗氧化活性检测. 华侨大学学报，2009

100 徐韬, 许瑞安*不同作用途径抗肿瘤中药的筛选与前瞻. 华侨大学学报, 2009， 108（33）， 359-365

101 吕颖慧，王启钊，肖卫东, 刁勇，许瑞安*. 自身互补型腺相关病毒载体研究进展.生物工程学报, 2009, 25(5):658~66.

102 刁勇, 许瑞安 口服重组腺相关病毒基因药物.药学学报, 2009, 44 (7): 703-709.

103 吴龙火; 王晓; 许瑞安* 九里香叶总黄酮提取工艺的研究. 广西轻工业, 2009,1:1-4.

104 唐明青; 刁勇; 许瑞安* 以壳聚糖为载体的口服基因药物. 中国生化药物杂志, 2009, 30(2):139-140.

105 王峰; 刁勇; 许瑞安* 重组腺相关病毒载体在肺癌治疗中的应用. 海峡药学, 2009, 21(3):8-11.

106 张红; 曾庆友; 林建明; 许瑞安* 白藜芦醇化学合成研究进. 精细化工中间体, 2009, 39(2):7-11.

107 曾庆友，曾明荣, 许瑞安* 对氧甲基肉桂酸乙酯一锅式绿色合成法 精细化工 2008, 28 (2)：192-4.

108 Wang Q，Lv Y, Xu RA*. Dose-response and control of adeno-associated viral vectors based preclinical and clinical gene therapy. Chinese Journal of Clinical Pharmacology and Therapeutics. 2008, 1:1182-1194.

109 舒静波，刁勇，许瑞安* 腺病毒-腺相关病毒嵌合纳米载体研究进展.华大学报 2008，29(2):172-176.

110 曾庆友，张红，许瑞安, 3，4-二甲氧基肉桂酸乙酯的一锅式合成. 青岛科技大学学报, 2008,(6)

111 李华; 陈陵霞; 许瑞安* 纤溶活性的药学测定方法研究. 中国临床药理学与治疗学. 2008, 13(9):1066-1070

112 曾庆友，曾明荣, 许瑞安* 对氧甲基肉桂酸甲酯一锅式绿色合成法.精细化工, 2008, 25 (2)：192-194.

113 曾庆友; 张红; 许瑞安; 3,4-二甲氧基肉桂酸乙酯的一锅式合成. 青岛科技大学学报, 2008, 29(6):490-492.

114 刁勇，局海亮, 许瑞安. 单环刺螠抗血栓组分的分离纯化和药效学研究. 中国生化药物学杂志, 2007；3：199-200.

115 吴龙火, 许瑞安.小胶质细胞及P38、MAPK 在圣经病理性疼痛中的作用. 科学研究, 38（2）:16-18, 2008.

116 许瑞安. 医用纳米与基因药物口服化的探索.中国药理学与药物治疗学. 2007,12: 1092-1097.54.

117 曾庆友; 曾明荣; 许瑞安; 对甲氧基肉桂酸甲酯的一锅式绿色合成. 化学合成， 2007, 15(5):663-664.

118 史娟, 刘彦信, 刘士廉, 许瑞安, 郑德先. 腺相关病毒介导Smac和DR5单链抗体表达对抑制肿瘤细胞生长的作用；中华医学杂志 2006, 86(26):1857-9. (SCI)

119 许瑞安*, 刁勇, 谢海棠. 基因药物在临床上的最新应用与研发.中国药理学与药物治疗学 2006, 11: 1092-7.

120 王佃亮; 刘万顺; 韩宝芹; 许瑞安; 张海智; 刘学英. 一种新型海洋纤溶酶体外抗凝与溶栓作用研究. 中国海洋药物, 2006, 25(4): 37-41

4. ABSTRACTS FOR INTERNATIONAL CONFERENCES AND GUEST SPEAERS：(2005.12—2011.1, total﹥50，partially list as below)

1 许瑞安 Cytoglubin抗肝纤维化的机理及其在临床应用前景 中国科学院广州生物健康研究院专题讲座 （特邀嘉宾）2008年 4月20日

2 许瑞安* 口服基因治疗 天津滨海高科技园 (邀请报告) 2010年9月26日

3 许瑞安* Function of Cytoglubin on anti-aging and application on skin protection. The Anit-aging Symposium Annual Meeing , June 29, 2008 （Invited speaker）台北，台湾

4 RA Xu* Double stranded microRNAs, a kind of potential anti-cancer agents, act similarly to siRNAs but with multi-targets BIT 3rd World Cancer Congress 2010 Singapore （Invited speaker）

5 RA Xu*, W Shi The recombinant Tat-CYGB protein, an anti-cancer agent for liver dease. AGST. 2010, May 15-19, Seattle, USA

6 Lu C, Wang Q, RA Xu Double-stranded Let-7 Mimics, a Kind of Potential Anti-cancer Agents AGST. 2010, May 15-19, Seattle, USA

7 曾庆友 张红，许瑞安 固体光气法合成3，4，5-三甲氧基苯甲酸酐，全国第15届有机和精细化工中间体学术交流会 2009.9.11-14 天津

8 Xu, RA*. Potential and Challenges of Diabetes gnene therapy BIT’S 1st Annual World Congress of Endobolism-2011, Xiamen, China ()

9 J.Shi, Y Liu, Y Guo, J Zhang, X Li, P-t Cheung, F Farzaneh, DX Zheng, RA Xu*. Expression of an Anti-DR5 Single Chain Antibody in Muscles of Nude Mice Prevents Cancer Growth. The 2nd International Cancer Meeting, Hong Kong, 2006

10 王峰 许瑞安 rAAV制备技术 福建省 2010年药理学年福州, 2010年 12月 22 日

11 XU RA*. Anti-angiogenic inhibitors on cancer gene therapy. ISCGT. 2005, December 9-11, Shenzhen, China

12 XU, RA*, Rahimi M, Ma H, Fung P, Farzaneh F, During MJ. Stability of infectious recombinant adeno-associated viral vector in gene delivery. ISCGT. 2005, December 9-11, Shenzhen, China

13 Tse L-Y. Xu RA*. Suppression of Hepatocellular carcinoma growth by kallistatin and vasostatin. ISCGT. 2005, December 9-11, Shenzhen, China

14 Liu Y, Guo Y, Tao X, Chn C, Liu S, XU RA*, Zheng DX. A novel anti- human DR5 monoclonical antibody with tumor –therapeutic potential. ISCGT. 2005, December 9-11, Shenzhen, China

15 Shi J, Zheng DX, Liu Y, Farzaneh F, Sham MH, XU RA*. TRAIL gene therapy of lung cancer. ISCGT. 2005, December 9-11, Shenzhen, China

16 Cai KX, Sham MH, Xiao W, Tam P, XU RA*. Angiogenic inhibitors suppresses lung cancer growth in spontaneous pulmonary metastasis mouse model. ISCGT. 2005, December 9-11, Shenzhen, China

17 Sun X, XU RA*, Farzaneh F, Krissensan GW. Over-expression of on Hippel-Lindau tumor suppressor protein and antisense HIF-1α eradicates gliomas. ISCGT. 2005, December 9-11, Shenzhen, China

18 Xu RA, PM Harrison, P-T Cheung, S Xu, F Farzaneh. Expression of cytoglobin inhibits hepatic stellate cell activation and liver fibrosis in toxic and cholestatic models of liver injury. The 41th ESLS Annual Meeting. 2006, Vienna, Austria

19 Xu RA*, Tse L-Y. Suppression of HCC growth by angiogenic inhibitors. The 41th ESLS Annual Meeting. 2006. Vienna, Austria

20 Dai J, Rabie AB, Xu RA. AAV mediated VEGF gene therapy to control mandibular condylar growth. 20th IADR-SEA travel award poster presentation. 2006, Malacca, Malaysia

21 Dai J, Rabie AB, Xu RA. Transduction characteristics of rAAV hybrids in chondrocytes and osteoblasts. IADR/Unilever Hatton Award competition Brisbane, 2006, February 22, Australia

22 Xu RA*. Anti-angiogenic agents for cancer therapy. The 4th Congress of International Drug Science and Technology. 2006, May 26- Jun 1, Dalian, China

23 Xu RA*, PM Harrison, M Chen, X Li, PT Cheung, W Xiao, F Farzaneh. Inhibition of hepatic stellate cell activation and liver fibrosis by expression of Cytoglobin in vivo. The 9th American Society of Gene Therapy Meeting. 2006, May 31-June 4. Baltimore, USA

24 Xu RA*, J Ma, Peter CW Fung, KW Chu, N Habib, F Farzaneh. Two new anti-angiogenic inhibitors for treatment of colon cancer. ISCGT. 2006, Japan

25 Xu, RA*, Kexia Cai, Paul Tam, Qizhao Wang, Mai Har Sham Suppression of Lung Tumor Metastasis in Mice by Recombinant Adeno-Associated Virus- mediated Expression of Vasostatin. ISCGT 2007, Nov 18-20. India. (Invited speaker)

26 RA Xu, X Li, Y Diao, P Harrison, W Xiao, N Habib, F Farzaneh. Long-term effect and biosafety of rAAV-rat Cygb expression AGST. 2007 June 1, Seattle, USA

27 Xu, RA, Qizhao Wang, Yinghui Lv. Dose-Response and Control in Viral Vectors Based Preclinical and Clinical Therapy. International Quantitative Pharmacology Conference 2007, October28-31, Nanijng, China (Invited speaker)

28 Xu, RA, Qizhao Wang, Yinghui Lv. miRNA in lung cancer. International Society for cell and gene therapy of Cancer (ISCGT) conference, 2008, Sep., Shijiazhuang,China (Invited speaker)（第五届中国肿瘤学术大会）

29 Qizhao Wang, Xu, RA microRNA in lung cancer. 第四届南北肺癌高峰论坛,2008,12, 29-20. 广州,中国.

30 王晓; 许瑞安. 第二届中草药提取关键技术与提取物产业应用研讨会. 厦门 2009

31 王启钊、吕颖慧、许瑞安 肿瘤基因治疗的思路与出路. 肿瘤病因学研究与中西医结合肿瘤综合整流交流研讨会论文集. 2009, 5, 7-9., 厦门.

32 Mingqing Tang, Qizhao Wang, Ruian Xu. DNMTs and its related epigenetic regulation in lung tumorigenesis. 肿瘤病因学研究与中西医结合肿瘤综合整流交流研讨会论文集. 2009, 5, 7-9. 厦门

33 许瑞安. Cytoglubin抗肝纤维化机理 (特邀嘉宾), 福建省 2008年药理学年福州,2008年 12月 16 日

34 许瑞安 生命科学的活力与分子药物学的张力 (特邀嘉宾) 泉州市药学年会讲 座, 2008年 11月 3日

35 Wang QZ, Habib N, Xiao W, Xu RA. Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy AGST 2009 May 30- June 2 , Boston, USA

36 Tang M, Wang Q, Xiao W., Xu RA* DNMTs and its related epigenetic regulation in lung tumorigenesis AGST. 2009 May 27-30 , Santiago, USA

37 Zhang Tingting, Li Z, Meng C, Xu RA* Mechanism of Anti-aging and Trends in Applications of Skin Anti-aging Pharmaceuticals 第十二届全国数学药理学术大会, 西宁, 8-10, 8,2009 (邀请嘉宾)

38 吴龙火、许瑞安 九里香中香豆素paniculal 的化学合成途径 2009 年全国药物化学学术会议 2009.10 武汉 中国

39 Xu RA*. Reducing de novo capsid synthesis from replication competent AAV contamination in the targeting tissue IT Life Sciences’3rd Annual World Congress of Gene 2009 (invited speaker)

OTHER ACEDMIC ACTIVITIES:

1. Council Excutive Member of International Society of Cell & Cancer Gene Therapy

2. Member of Editorial Board of Islet (Swenden)；

3. International Panel of Medical Science Monitor （USA）；

4. Member of Editorial Board of World Journal of Gastroenterology Pharmacology and Treatment；

5. Member of Editorial Board of World Journal of Hepatology；

6. Member of Editorial Board of World Journal of Clinical Oncology；

7. Reviewer of Hepatology （USA）；

8. Reviewer of Gene Therapy (USA)；

9. Reviewer of Journal of Applied Polymer Sciences；

10. Reviewer of International Journal of Cancer (Germany)；

11. Reviewer of Apoptosis (USA)；

12. Reviewer of Applied Biochemistry and Biotechnology (USA)；

13. Reviewer of Journal of Pharmacy and Pharmacology (UK)；

14. Reviewer of Jounral Biomedical Science；

15. Reviewer of Tumor Biology (Swenden)；

16. Reviewer of JPP (USA)

17. Reviewer of Journal of Cellular Physiology (USA)

18. Reviewer of Cancer Immunology Immunotherapy

19. Reviewer of Cancer Letter

20. Reviewer of Irish National Health Research Grant

21. Scientific Committee member of 2006 Cancer Gene Therapy, Japan.

22. Chairman of 2nd International Conference of Clinical Quantitative Pharmacology and New Drug Evaluation, October 29-31, 2010.

23. BIT’S 1st Annual World Congress of Endobolism-2011 (大会主持人)

24. 丰泽区政府社会经济顾问；

25. 晋江市人民政府顾问团顾问；

26. 泉州（永春）生物医药产业顾问团顾问；

27. 泉州市抗癌协会顾问；

28. 泉州市中药现代化工程中心主任；

29. 泉州医药同业会高级顾问；

30. 泉州市人民政府技术创新工程专家顾问；

31. 厦门市科技局评审专家；

32. 福建省药物化学重点实验室副主任；

33. 安徽省临床药物评价中心顾问；

34. 《中国临床药理学和治疗学》编委、顾问；

35. 《中国海洋资源》特邀编委；

36. 科技部科技发展战略专家；

37. 科技部国际合作管理专家；

38. 科技部企业技术专家；

39. 国家自然科学基金网上评审专家。

SUPERVISON OF PHD STUDENTS: Total: 21 （16 graduated）

SUPERVISON OF MSC STUDENTS Total: 39 （29 graduated）